Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

##STR00001##

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

##STR00001##

Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment.

Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment.

The present invention provides contrast agents of the formula [N(A.sub.1,A.sub.2,A.sub.3) M](counter ion(s)) for use in a diagnostic method practiced on the human or animal body. It also refers to the contrast agents, as well as pharmaceutical compositions containing same. Further, it relates to a method of in vitro medical imaging, especially of diagnostic imaging, comprising administering said compound to a sample.

The present invention provides contrast agents of the formula [N(A.sub.1,A.sub.2,A.sub.3) M](counter ion(s)) for use in a diagnostic method practiced on the human or animal body. It also refers to the contrast agents, as well as pharmaceutical compositions containing same. Further, it relates to a method of in vitro medical imaging, especially of diagnostic imaging, comprising administering said compound to a sample.

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. ##STR00001##

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. ##STR00001##

Hydrotetrazine compounds having antioxidant properties and uses thereof are described herein. These compounds may be dihydrotetrazines, tetrahydrotetrazines, or hexahydrotetrazines that can be utilized as antioxidants for use in thermoplastics, thermosets and elastomers; free radical inhibitors to stabilize reactive chemicals, such as monomers against free radical polymerizations; and as anticorrosion agents in coatings to protect against metal oxidation. The hydrogenated tetrazines can donate hydrogen atom equivalents to terminate radical chain reactions. These compounds can change colors to signal when oxidation has occurred, and can be further recycled by reduction reactions.

Hydrotetrazine compounds having antioxidant properties and uses thereof are described herein. These compounds may be dihydrotetrazines, tetrahydrotetrazines, or hexahydrotetrazines that can be utilized as antioxidants for use in thermoplastics, thermosets and elastomers; free radical inhibitors to stabilize reactive chemicals, such as monomers against free radical polymerizations; and as anticorrosion agents in coatings to protect against metal oxidation. The hydrogenated tetrazines can donate hydrogen atom equivalents to terminate radical chain reactions. These compounds can change colors to signal when oxidation has occurred, and can be further recycled by reduction reactions.